At the news
? BEARISHIMPACT 6/10 COURT-RULING filed Aug 30, 2026 at 20:00 ET
A federal magistrate judge granted plaintiff's motion to strike several key exhibits that Moderna had submitted in support of its motion to dismiss a securities fraud class action over alleged misrepresentations regarding mRESVIA RSV vaccine clinical trial data. The ruling weakens Moderna's ability to have the case dismissed early, increasing litigation risk for the company.
- Moderna is a defendant in a securities fraud class action over alleged misrepresentations about RSV vaccine (mRESVIA) clinical trial efficacy data.
- Plaintiff's motion to strike Moderna's exhibits (Exhibits 20-22, 80-1, 80-2, 72-17 through 72-19, 72-32 through 72-37, 72-41) was ALLOWED.
- Exhibit 20 (FDA email requesting data) appeared to 'gravely undercut' plaintiff's claims but was excluded due to authenticity challenge.
- The court noted the exhibits were not essential to deciding the motion to dismiss and could be re-filed at summary judgment stage.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access